Senzime, Webcast press conference, 2022

Senzime has entered into an agreement to acquire the US company Respiratory Motion

Senzime AB (publ) (”Senzime” or the ”Company”) has today signed an agreement to acquire 100 percent of the shares in the US company Respiratory Motion, Inc. (“Respiratory Motion”) for an initial consideration of USD 19 million on a cash- and debt-free basis (the “Initial Consideration”) with an additional potential earn-out payment of up to USD 25 million, paid out earliest in 2024 (the “Transaction”). The sellers consist of a larger group of individuals and companies, some of whom are employees of the company and others are professional investors (the “Sellers”). Through the acquisition, Senzime expands its product portfolio within the market for monitoring of vital signs and extends the Company’s capability to capture a larger share of the patient journey outside of the operating room as well. To finance the Initial Consideration, Senzime’s Board of Directors has resolved to summon an Extraordinary General Meeting to authorize the Board of Directors to resolve on an issue through set-off of preliminary 8,655,238 shares (the “Consideration Shares”). In addition, Senzime will conduct a new share issue of approximately SEK 100 million to finance working capital needs in Respiratory Motion and accelerate the growth journey, directed to Swedish and international institutional investors through an accelerated book-building procedure, which is expected to commence today (the “Directed Share Issue”).

More info:

https://senzime.com/mfn_news/senzime-has-entered-into-an-agreement-to-acquire-the-us-company-respiratory-motion/